Combined Patching-Atropine for Residual Amblyopia

Summary

Combined Patching-Atropine for Residual Amblyopia is a clinical trial^[1].

Key Facts

• Combined Patching-Atropine for Residual Amblyopia is in the country of United States^[2].
• Combined Patching-Atropine for Residual Amblyopia's instance of is recorded as clinical trial^[3].
• Combined Patching-Atropine for Residual Amblyopia's start time is recorded as +2007-10-31T00:00:00Z^[4].
• Combined Patching-Atropine for Residual Amblyopia's end time is recorded as +2009-04-30T00:00:00Z^[5].
• Combined Patching-Atropine for Residual Amblyopia's main subject is recorded as amblyopia^[6].
• Combined Patching-Atropine for Residual Amblyopia's number of participants is recorded as {'unit': '1', 'amount': '+55'}^[7].
• Combined Patching-Atropine for Residual Amblyopia's title is recorded as A Randomized Trial to Evaluate Combined Patching-Atropine for Residual Amblyopia^[8].
• Combined Patching-Atropine for Residual Amblyopia's short name is recorded as ATS11^[9].
• Combined Patching-Atropine for Residual Amblyopia's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+3'}^[10].
• Combined Patching-Atropine for Residual Amblyopia's ClinicalTrials.gov ID is recorded as NCT00506675^[11].
• Combined Patching-Atropine for Residual Amblyopia's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+9'}^[12].
• Combined Patching-Atropine for Residual Amblyopia's research intervention is recorded as atropine^[13].
• Combined Patching-Atropine for Residual Amblyopia's clinical trial phase is recorded as phase III clinical trial^[14].
• Combined Patching-Atropine for Residual Amblyopia's research site is recorded as Duke Eye Center^[15].
• Combined Patching-Atropine for Residual Amblyopia's research subject recruitment status is recorded as terminated^[16].
• Combined Patching-Atropine for Residual Amblyopia's study type is recorded as interventional study^[17].